Imagine a
world without allergies
Desentum’s mission is to expand the use of allergen immunotherapy (AIT) world-wide by introducing novel, effective, safe and patient-friendly AIT products that are well-documented and approved by the regulatory authorities. Our lead development programs include treatments for birch pollen, grass pollen and peanut allergies.
Desentum’s products are investigational and not approved for marketing in any region.
Technology
Our immunotherapeutic products consist of recombinant allergens specifically modified to suppress the histamine release during the desensitization process. They can significantly reduce the risk of serious adverse effects and the time required for immunotherapy.
Desentum
Desentum is a clinical-stage biopharmaceutical company developing novel types of allergen immunotherapy products that actually change the way the immune system reacts to allergens. We have a unique technology that can lead to major improvements in the future treatment of allergies.
News
Desentum raises €8 million in minutes – the company’s allergy vaccine may cut immunotherapy duration from years to months
Desentum is developing novel allergen immunotherapy designed to make treatment faster, more effective, and safer. Finnish private investors and family offices invested €8 million in an exceptionally rapid share issue.
New scientific discovery about the molecular mechanism of allergic reaction sheds light on the severity of peanut allergy
A single Ara h 2 allergen can bind simultaneously three copies of an IgE antibody commonly found in peanut allergic patients. This enables the formation of large allergen-IgE complexes on mast cell or basophil surfaces and contributes to the potency of Ara h 2 in triggering allergic reactions and highlights its role in anaphylaxis.
Enrolment completed in Phase 2 clinical study with DM-101PX, a novel immunotherapy for treating birch pollen allergy
Desentum, a clinical-stage biotechnology company developing novel allergen immunotherapies, today announced that its...